| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA589301
Max Phase: Preclinical
Molecular Formula: C18H22N2O4
Molecular Weight: 330.38
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: O=C([C@@H]1O[C@H]2CN(Cc3ccccc3)C(=O)[C@@H]1O2)N1CCCCC1
Standard InChI: InChI=1S/C18H22N2O4/c21-17(19-9-5-2-6-10-19)15-16-18(22)20(12-14(23-15)24-16)11-13-7-3-1-4-8-13/h1,3-4,7-8,14-16H,2,5-6,9-12H2/t14-,15-,16-/m1/s1
Standard InChI Key: BKJXHTXGHDYMGI-BZUAXINKSA-N
Associated Targets(Human)
Beta-secretase 1 15641 Activities
Associated Targets(non-human)
Candidapepsin-2 159 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Candida albicans 78123 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Protease 2551 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 330.38 | Molecular Weight (Monoisotopic): 330.1580 | AlogP: 1.15 | #Rotatable Bonds: 3 |
| Polar Surface Area: 59.08 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
| #RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 13.07 | CX Basic pKa: | CX LogP: 1.30 | CX LogD: 1.30 |
| Aromatic Rings: 1 | Heavy Atoms: 24 | QED Weighted: 0.83 | Np Likeness Score: -0.48 |
References
| 1. Trabocchi A, Mannino C, Machetti F, De Bernardis F, Arancia S, Cauda R, Cassone A, Guarna A.. (2010) Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds., 53 (6): [PMID:20184325] [10.1021/jm901734u] |
| 2. Calugi C, Trabocchi A, De Bernardis F, Arancia S, Navarra P, Cauda R, Cassone A, Guarna A.. (2012) Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype., 20 (24): [PMID:23123016] [10.1016/j.bmc.2012.09.031] |
| 3. Calugi C, Guarna A, Trabocchi A.. (2014) Identification of constrained peptidomimetic chemotypes as HIV protease inhibitors., 84 [PMID:25042102] [10.1016/j.ejmech.2014.07.049] |
| 4. Innocenti R, Lenci E, Menchi G, Pupi A, Trabocchi A.. (2017) Design and synthesis of bicyclic acetals as Beta Secretase (BACE1) inhibitors., 25 (19): [PMID:28359674] [10.1016/j.bmc.2017.03.030] |
| 5. Liu N, Tu J, Dong G, Wang Y, Sheng C.. (2018) Emerging New Targets for the Treatment of Resistant Fungal Infections., 61 (13): [PMID:29294275] [10.1021/acs.jmedchem.7b01413] |
Source
Source(1):